Triple negative breast cancer (TNBC) is defined by the clinical laboratory evaluation revealing a lack of expression of ER, PR and HER2 receptors, accounts for 10% to 20% of all breast cancer[18], and has a higher rate of distant recurrence and a poorer prognosis than other breast cancer subtypes [19,20]. The gene discussed is ESR1; the disease is breast cancer.